Background: GLS-010 is a novel fully human anti-PD-1 mAb. Previous Phase 1 study exhibited favorable result of tolerance, preliminary efficacy and 240mg fixed dose q2w was selected as Recommended Phase 2 Dose (RP2D). This Phase 2 clinical trial is aimed to further evaluate the safety and efficacy profile of GLS-010 in Chinese patients(pts) with relapsed or refractory classical Hodgkin’s Lymphoma( r/r cHL). Here we reported the preliminary result. Methods: All pts enrolled received GLS-010 240mg every 2 weeks. Tumor response was assessed by Lugona 2014 every 8 weeks. Adverse events (AEs) were graded by NCI CTCAE v4.03. Results: Until Jan 30^th 2019, 39 pts were enrolled in this ongoing study. The median dosing number was 4 (range: 1~12). 17 pts received response evaluation. Of 17 evaluable subjects, an objective response was reported in 15 patients (88.3%), including 4(23.5%) pts with a complete response(CR) and 11 pts(64.7% )with a partial response(PR), 1 patient(5.9%) with stable disease(SD)and 1 remaining patient(5.9%) with unconfirmed progressive disease(PD)(observed stable disease(SD) in the first assessment).The most common treatment related AEs included Neutrophil count decreased (10/32), White blood cell count decreased (7/32), Fever (6/32), Alanine aminotransferase increased (4/32), etc. Treatment–related grade 3-5 AEs include Neutrophil count decreased (2/6), Interstitial lung disease (1/6), Influenza like illness (1/6). Conclusions: GLS-010 showed impressive therapeutic activity and an acceptable safety profile in Chinese r/r cHL patients. Current evidence support further development of GLS-010 in this and more indications. Clinical trial information: NCT03655483